Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease

Página do item simplificado
dc.contributor.authorFerrari, Renata [UNESP]
dc.contributor.authorTanni, Suzana E. [UNESP]
dc.contributor.authorCaram, Laura M.O. [UNESP]
dc.contributor.authorCorrêa, Corina [UNESP]
dc.contributor.authorCorrêa, Camila Renata [UNESP]
dc.contributor.authorGodoy, Irma de [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:28:31Z
dc.date.available2014-05-27T11:28:31Z
dc.date.issued2013-02-20
dc.description.abstractBackground: Past studies have shown that mean values of Interleukin-6 (IL-6) and C-reactive protein (CRP) do not change significantly in COPD patients over a one-year period. However, longer period follow-up studies are still lacking. Thus, the aim of this study is to evaluate plasma CRP and IL-6 concentration over three years in COPD patients and to test the association between these inflammatory mediators and disease outcome markers. Methods: A cohort of 77 outpatients with stable COPD was evaluated at baseline, and 53 (mean FEV1, 56% predicted) were included in the prospective study. We evaluated Interleukin-6 (IL-6), C-reactive protein (CRP), six-minute walking distance (6MWD), and body mass index (BMI) at baseline and after three years. Plasma concentration of IL-6 was measured by high sensitivity ELISA, and CRP was obtained by high sensitivity particle-enhanced immunonephelometry. Results: IL-6 increased significantly after 3 years compared to baseline measurements [0.8 (0.5-1.3) vs 2.4 (1.3-4.4) pg/ml; p < 0.001] and was associated with worse 6MWD performance. In the Cox regression, increased IL-6 at baseline was associated with mortality [Hazard Ratio (95% CI) = 2.68 (0.13, 1.84); p = 0.02]. CRP mean values did not change [5 (1.6-7.9) vs 4.7 (1.7-10) pg/L; p = 0.84], although eleven patients (21%) presented with changes >3 mg/L in CRP after 3 years. Conclusions: The systemic inflammatory process, evaluated by IL-6, seems to be persistent, progressive and associated with mortality and worse physical performance in COPD patients. Trial registration: No.:NCT00605540. © 2013 Ferrari et al; licensee BioMed Central Ltd.en
dc.description.affiliationFaculdade de Medicina de Botucatu Univ Estadual Paulista, Unesp Disciplina de Pneumologia, Botucatu, São Paulo
dc.description.affiliationUnespFaculdade de Medicina de Botucatu Univ Estadual Paulista, Unesp Disciplina de Pneumologia, Botucatu, São Paulo
dc.identifierhttp://dx.doi.org/10.1186/1465-9921-14-24
dc.identifier.citationRespiratory Research, v. 14, n. 1, 2013.
dc.identifier.doi10.1186/1465-9921-14-24
dc.identifier.file2-s2.0-84873948021.pdf
dc.identifier.issn1465-9921
dc.identifier.issn1465-993X
dc.identifier.lattes5079454858778041
dc.identifier.scopus2-s2.0-84873948021
dc.identifier.urihttp://hdl.handle.net/11449/74616
dc.identifier.wosWOS:000317734600001
dc.language.isoeng
dc.relation.ispartofRespiratory Research
dc.relation.ispartofjcr3.751
dc.relation.ispartofsjr1,644
dc.rights.accessRightsAcesso aberto
dc.sourceScopus
dc.subjectBiomarkers
dc.subjectChronic Obstructive Pulmonary Disease
dc.subjectExercise
dc.subjectInflammation
dc.subjectC reactive protein
dc.subjectinterleukin 6
dc.subjectbiological marker
dc.subjectIL6 protein, human
dc.subjectadult
dc.subjectbody mass
dc.subjectchronic obstructive lung disease
dc.subjectclinical evaluation
dc.subjectcontrolled study
dc.subjectdisease association
dc.subjectdisease duration
dc.subjectdisease exacerbation
dc.subjectenzyme linked immunosorbent assay
dc.subjectexercise tolerance
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmortality
dc.subjectnutritional status
dc.subjectoutcome assessment
dc.subjectprediction
dc.subjectproportional hazards model
dc.subjectprospective study
dc.subjectprotein blood level
dc.subjectwalking
dc.subjectblood
dc.subjectBrazil
dc.subjectexercise test
dc.subjectmiddle aged
dc.subjectprevalence
dc.subjectrisk factor
dc.subjectstatistics
dc.subjectsurvival
dc.subjectsurvival rate
dc.subjectBiological Markers
dc.subjectC-Reactive Protein
dc.subjectExercise Test
dc.subjectExercise Tolerance
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectInterleukin-6
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPrevalence
dc.subjectPulmonary Disease, Chronic Obstructive
dc.subjectRisk Factors
dc.subjectSurvival Analysis
dc.subjectSurvival Rate
dc.titleThree-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary diseaseen
dc.typeArtigo
dcterms.licensehttp://www.biomedcentral.com/about/license
unesp.author.lattes5079454858778041
unesp.author.orcid0000-0002-5863-2006[3]
unesp.author.orcid0000-0002-6588-5626[6]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatupt
unesp.departmentClínica Médica - FMBpt

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
2-s2.0-84873948021.pdf
Tamanho:
366.99 KB
Formato:
Adobe Portable Document Format
Baixar

Coleções

Botucatu - FMB - Faculdade de Medicina